Cargando…
Treatment of HFpEF beyond the SGLT2-Is: Does the Addition of GLP-1 RA Improve Cardiometabolic Risk and Outcomes in Diabetic Patients?
Heart failure with preserved ejection fraction (HFpEF) is a common clinical syndrome frequently seen in elderly patients, the incidence of which is steadily increasing due to an ageing population and the increasing incidence of diseases, such as diabetes, hypertension, obesity, chronic renal failure...
Autores principales: | Belli, Martina, Barone, Lucy, Bellia, Alfonso, Sergi, Domenico, Lecis, Dalgisio, Prandi, Francesca Romana, Milite, Marialucia, Galluccio, Chiara, Muscoli, Saverio, Romeo, Francesco, Barillà, Francesco |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9737325/ https://www.ncbi.nlm.nih.gov/pubmed/36498924 http://dx.doi.org/10.3390/ijms232314598 |
Ejemplares similares
-
Biomolecular Mechanisms of Cardiorenal Protection with Sodium-Glucose Co-Transporter 2 Inhibitors
por: Prandi, Francesca Romana, et al.
Publicado: (2022) -
Obesity and HFpEF
por: Clemenza, Francesco, et al.
Publicado: (2022) -
Epigenetic Modifications and Non-Coding RNA in Diabetes-Mellitus-Induced Coronary Artery Disease: Pathophysiological Link and New Therapeutic Frontiers
por: Prandi, Francesca Romana, et al.
Publicado: (2022) -
Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF
por: Bode, David, et al.
Publicado: (2021) -
SGLT2 inhibitors in patients with HFpEF: how old is too old?
por: Tong, Dan
Publicado: (2022)